Geron Announces NCCN Guidelines Update for RYTELO™ in Lower-Risk MDS
Geron Corporation (Nasdaq: GERN) has announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include RYTELO™ (imetelstat) as a recommended treatment for symptomatic anemia in lower-risk myelodysplastic syndromes (MDS). The updated guidelines categorize RYTELO…
New Study Shows Signatera’s Utility in Merkel Cell Carcinoma
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced a new study in the Journal of Clinical Oncology showcasing the effectiveness of its personalized molecular residual disease (MRD) test, Signatera, for monitoring Merkel cell carcinoma (MCC). The…
Fujirebio Unveils Automated Lumipulse® G GFAP Assay for Research
HU Group Holdings Inc. and its subsidiary, Fujirebio, have announced the launch of the Lumipulse G GFAP assay for use on the fully automated, random-access LUMIPULSE® G immunoassay systems. This research-use only (RUO) assay is now available in the United…
Insulet Q2 2024 Revenue Preview
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has announced preliminary revenue results for Q2 2024, ending June 30. Full financial results will be reported on August 8, 2024, followed by a conference…
Schrödinger Launches Initiative to Broaden Computational Tools for Predictive Toxicology
Schrödinger, Inc. (Nasdaq: SDGR), renowned for its physics-based computational platform, is launching a new initiative to enhance early-stage drug discovery by predicting toxicology risks. This project aims to improve drug development candidates by minimizing the risk of adverse effects from…
Althaia Teams Up with Robbie AI to Prevent Falls in Frail Hospital Patients
The Althaia Foundation is launching an innovative project to prevent falls in frail hospitalized patients using artificial intelligence. In collaboration with Robbie AI, this initiative aims to help healthcare professionals anticipate fall risks and take preventive actions. The pilot study…
Amprion Debuts Next-Gen SAAmplify™ Panels for Neurodegenerative Diagnosis at AAIC 2024
Amprion, a leader in advancing the diagnosis of neurodegenerative disorders through seed amplification testing, is unveiling its new line of cerebrospinal fluid (CSF) biomarker panels under the SAAmplify brand. These panels provide physicians and patients with the most comprehensive biomarkers…
Merck Gets Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® in Urothelial Carcinoma
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in…
Glycocalyx Institute Reveals Study Linking Microvascular Health to Fewer Cancer Therapy Side Effects
The Glycocalyx Research Institute is excited to announce groundbreaking results from a recent study exploring the impact of microvascular health—comprising the vast network of tiny capillaries in the body—on acute side effects from radiation therapy in breast, prostate, and head…
Eisai Chooses Medidata’s Data Studio to Boost Clinical Trial Efficiency
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, has announced that Eisai Inc. (the U.S. subsidiary of Tokyo-based Eisai Co., Ltd.) is among the first to adopt its new AI-driven Medidata Clinical Data Studio. Eisai will…
Azitra, Inc. Closes $10M Public Offering
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the successful closing of its public offering. The offering comprised 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 additional…
Maverick Medical AI Expands US Presence Through New Partnership for Real-Time Medical Coding Solution
Maverick Medical AI has announced a significant expansion of its presence in the United States through a new partnership with a leading national medical provider specializing in the outpatient radiology sector. Within just three months, Maverick successfully transitioned the provider…